2026 First Quarter Legislative Wrap Up highlights state psychedelic policy bills across New York, Utah, Massachusetts, Washington, New Jersey, and Colorado

State psychedelic policy in 2026 is framed through a first-quarter legislative roundup of proposals across multiple US states. New York’s A3845A proposes a state-funded psilocybin-assisted therapy pilot for 10,000 veterans, first responders, and people with cluster headaches, with oversight, licensure protections, and data collection. Utah’s HB 390 authorizes a donation-funded clinical study on the safety and feasibility of psychedelic-assisted therapy for veterans with treatment-resistant PTSD and reports that it has already been enacted as of March 4, 2026. Massachusetts advances two research-focused pilots for psychedelics in licensed treatment facilities and access to regulated psilocybin. Washington’s WNPSAA would allow personal possession, cultivation, and non-commercial sharing of psilocybin and related tryptamines for adults, paired with safety-first pathways for psychedelic-assisted services and restrictions intended to prevent commercialization. New Jersey’s signed law creates a hospital-based psilocybin behavioral health pilot with a research advisory board. Colorado’s HB 26-1325 would establish a state-federal ibogaine research pilot aimed at opioid and mental health needs, emphasizing federal compliance, safety protocols, and an Ibogaine Implementation Cash Fund.